TSE:HBP

Helix BioPharma Stock Forecast, Price & News

C$0.83
-0.09 (-9.78 %)
(As of 04/12/2021 03:59 PM ET)
Add
Compare
Today's Range
C$0.83
Now: C$0.83
C$0.93
50-Day Range
C$0.75
MA: C$0.83
C$0.91
52-Week Range
C$0.25
Now: C$0.83
C$1.60
Volume12,448 shs
Average Volume48,170 shs
Market CapitalizationC$117.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-416-9253232
Employees10
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.03 per share
Book ValueC$0.03 per share

Profitability

Miscellaneous

Market CapC$117.14 million
Next Earnings Date7/29/2021 (Estimated)
OptionableOptionable

Headlines

HBP.TO: Private Placement Completed
December 28, 2020 |  finance.yahoo.com
Helix BioPharma closes divesture of Polish subsidiary
December 23, 2020 |  proactiveinvestors.com
Helix BioPharma Corp.
October 24, 2020 |  barrons.com
Helix BioPharma Corp - Proactive One2One Virtual Event
August 12, 2020 |  proactiveinvestors.com
Stocks in play: Helix BioPharma Corp.
June 22, 2020 |  ca.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

0.46 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
C$0.83
-0.09 (-9.78 %)
(As of 04/12/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HBP News and Ratings via Email

Sign-up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Helix BioPharma (TSE:HBP) Frequently Asked Questions

What stocks does MarketBeat like better than Helix BioPharma?

Wall Street analysts have given Helix BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Helix BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Helix BioPharma's next earnings date?

Helix BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Helix BioPharma
.

How has Helix BioPharma's stock price been impacted by Coronavirus?

Helix BioPharma's stock was trading at C$1.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HBP shares have decreased by 48.1% and is now trading at C$0.83.
View which stocks have been most impacted by COVID-19
.

Who are Helix BioPharma's key executives?

Helix BioPharma's management team includes the following people:
  • Dr. Heman Chao, CEO, Chief Scientific Officer, Member of Scientific & Strategic Advisory Board and Director (Age 58, Pay $301.03k)
  • Mr. Photios Michalargias C.A., CPA, CPA, CA, Chief Financial Officer (Age 58, Pay $285.47k)
  • Mr. Pawel Wisniewski, Chief Exec. Officer of Poland

Who are some of Helix BioPharma's key competitors?

What other stocks do shareholders of Helix BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Helix BioPharma investors own include Lakeland Industries (LAKE), Liquidia (LQDA), Ovintiv (OVV), SIG (SHI), The Green Organic Dutchman (TGOD), Zynerba Pharmaceuticals (ZYNE), American Airlines Group (AAL), Aurora Cannabis (ACB), Apollo Investment (AINV) and Aphria (APHA).

What is Helix BioPharma's stock symbol?

Helix BioPharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HBP."

How do I buy shares of Helix BioPharma?

Shares of HBP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Helix BioPharma's stock price today?

One share of HBP stock can currently be purchased for approximately C$0.83.

How much money does Helix BioPharma make?

Helix BioPharma has a market capitalization of C$117.14 million.

How many employees does Helix BioPharma have?

Helix BioPharma employs 10 workers across the globe.

What is Helix BioPharma's official website?

The official website for Helix BioPharma is www.helixbiopharma.com.

Where are Helix BioPharma's headquarters?

Helix BioPharma is headquartered at 21 St Clair Ave E Suite 1100, TORONTO, ON M4T 1L9, Canada.

How can I contact Helix BioPharma?

Helix BioPharma's mailing address is 21 St Clair Ave E Suite 1100, TORONTO, ON M4T 1L9, Canada. The biopharmaceutical company can be reached via phone at +1-416-9253232.


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.